M M Uygur1, D Dereli Yazıcı2, D Gogas Yavuz3. 1. Deparment of Internal Medicine, Division of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey. muygur@marmara.edu.tr. 2. Deparment of Internal Medicine, Division of Endocrinology and Metabolism Diseases, Koc University School of Medicine, Istanbul, Turkey. 3. Deparment of Internal Medicine, Division of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey.
Abstract
INTRODUCTION: Elevated fibroblast growth factor-21 (FGF-21) levels are related to carotid intima-media thickness (CIMT), a well-established marker of atherosclerosis. Acromegaly has also been linked to increased CIMT. There has been no data considering the association between FGF-21 levels and atherosclerosis in acromegaly patients. This study aimed to evaluate FGF-21 levels and CIMT in acromegalic patients in relation to atherosclerotic complications. DESIGN: Case-control study. MATERIALS AND METHODS: The study group included 70 acromegaly patients and 72 healthy volunteers from the Department of Endocrinology and Metabolism Disease, Marmara University Medical School. FGF-21, growth hormone, insulin-like growth factor I, lipids, glucose, insulin levels were assessed. CIMT was measured from the common carotid artery wall on B-mode ultrasound. RESULTS: Median FGF-21 levels were significantly lower in the acromegaly group than in the control group. CIMT was higher in acromegaly patients compared to controls. Although there was no correlation between FGF-21 levels and CIMT in patients with acromegaly, a positive correlation was found between high-density lipoprotein-cholesterol and FGF-21 levels. Glucose metabolic markers were the determining factors of the FGF-21 levels in acromegaly patients. CONCLUSION: Our study is the first to examine the relationship between serum FGF-21 levels and atherosclerosis in acromegaly patients. The lower serum FGF-21 levels in acromegaly subjects might be associated with the improving effects of growth hormone on liver fat. Acromegaly was linked to higher CIMT, but there was no correlation between FGF-21 levels and CIMT. The role of FGF-21 in acromegaly as a marker of atherosclerosis requires additional research.
INTRODUCTION: Elevated fibroblast growth factor-21 (FGF-21) levels are related to carotid intima-media thickness (CIMT), a well-established marker of atherosclerosis. Acromegaly has also been linked to increased CIMT. There has been no data considering the association between FGF-21 levels and atherosclerosis in acromegaly patients. This study aimed to evaluate FGF-21 levels and CIMT in acromegalic patients in relation to atherosclerotic complications. DESIGN: Case-control study. MATERIALS AND METHODS: The study group included 70 acromegaly patients and 72 healthy volunteers from the Department of Endocrinology and Metabolism Disease, Marmara University Medical School. FGF-21, growth hormone, insulin-like growth factor I, lipids, glucose, insulin levels were assessed. CIMT was measured from the common carotid artery wall on B-mode ultrasound. RESULTS: Median FGF-21 levels were significantly lower in the acromegaly group than in the control group. CIMT was higher in acromegaly patients compared to controls. Although there was no correlation between FGF-21 levels and CIMT in patients with acromegaly, a positive correlation was found between high-density lipoprotein-cholesterol and FGF-21 levels. Glucose metabolic markers were the determining factors of the FGF-21 levels in acromegaly patients. CONCLUSION: Our study is the first to examine the relationship between serum FGF-21 levels and atherosclerosis in acromegaly patients. The lower serum FGF-21 levels in acromegaly subjects might be associated with the improving effects of growth hormone on liver fat. Acromegaly was linked to higher CIMT, but there was no correlation between FGF-21 levels and CIMT. The role of FGF-21 in acromegaly as a marker of atherosclerosis requires additional research.
Authors: Annamaria Colao; Ludovica F S Grasso; Andrea Giustina; Shlomo Melmed; Philippe Chanson; Alberto M Pereira; Rosario Pivonello Journal: Nat Rev Dis Primers Date: 2019-03-21 Impact factor: 52.329
Authors: Wing Sun Chow; Aimin Xu; Yu Cho Woo; Annette W K Tso; Stephen C W Cheung; Carol H Y Fong; Hung Fat Tse; Ming Tak Chau; Bernard M Y Cheung; Karen S L Lam Journal: Arterioscler Thromb Vasc Biol Date: 2013-07-25 Impact factor: 8.311
Authors: Laurie R Braun; Meghan N Feldpausch; Natalia Czerwonka; Martin Torriani; Steven K Grinspoon; Takara L Stanley Journal: Growth Horm IGF Res Date: 2017-10-07 Impact factor: 2.372
Authors: B S Yurekli; N O Kutbay; M Aksit; A Suner; I Y Simsir; S Seckiner; G U Kocabas; G Bozkaya; F Saygili Journal: J Endocrinol Invest Date: 2018-05-12 Impact factor: 4.256
Authors: Susan L Samson; Lisa B Nachtigall; Maria Fleseriu; Murray B Gordon; Marek Bolanowski; Artak Labadzhyan; Ehud Ur; Mark Molitch; William H Ludlam; Gary Patou; Asi Haviv; Nienke Biermasz; Andrea Giustina; Peter J Trainer; Christian J Strasburger; Laurence Kennedy; Shlomo Melmed Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958